Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Delays Decision on J & J Ovarian Cancer Drug

By Pharmaceutical Processing | September 11, 2009

HORSHAM, Pa. (AP) — A unit of Johnson and Johnson said Thursday federal health regulators want more information on its experimental treatment for ovarian cancer before making an approval decision. J&J said the Food and Drug Administration requested more data, including overall survival rates from patients enrolled in an ongoing company study. “The company is reviewing the FDA’s letter and will respond to the agency’s questions as quickly as possible,” said the company’s Centocor Ortho Biotech division, in a statement. In July the FDA’s oncology panel voted 14-1 against the injectable drug, called Yondelis, which J&J hopes to market as a treatment for women with recurring ovarian cancer. It would be used in combination with the company’s cancer drug Doxil. The panel said the drug’s benefits did not outweigh its risks, including blood toxicity, anemia and heart problems. The FDA is not required to follow the group’s advice, though it usually does. In a preliminary review released ahead of the meeting, FDA said it was considering whether to wait for more data on survival rates before making a decision on the drug.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE